Ascentage Pharma Announces Clinical Data of Lisaftoclax, Which Shows Therapeutic Potential in Venetoclax-Refractory Patients, Selected for Oral Report at ASCO 2025

Ascentage Pharma Announces Clinical Data of Lisaftoclax, Which Shows Therapeutic Potential in Venetoclax-Refractory Patients, Selected for Oral Report at ASCO 2025 GlobeNewswire May 23, 2025 ROCKVILLE, Md. and SUZHOU, China, May 22, 2025 (GLOBE NEWSWIRE) — Ascentage Pharma (NASDAQ: AAPG; HKEX: 6855), a global biopharmaceutical company dedicated to addressing unmet medical needs in cancers, today […]

Inclusive Design Gains Momentum as Canton Fair Spotlights Senior-Friendly Innovation

As global demographics shift, the aging population becomes a defining force in product innovation. At the 137th China Import and Export Fair (Canton Fair), Chinese companies have been embracing this trend with technology-driven, senior-centric solutions designed to promote safety, independence, and dignity for older adults. One standout exhibitor, Guangzhou SELAQUA Sanitary Ware Co., Ltd. (Aicube

ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages UnitedHealth Group Incorporated Investors to Secure Counsel Before Important Deadline in Securities Class Action Commenced by the Firm- UNH

(NYSE:UNH), NEW YORK, May 22, 2025 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of UnitedHealth Group Incorporated (NYSE: UNH) between December 3, 2024 and May 12, 2025, both dates inclusive (the “Class Period”), of the important July 7, 2025 lead plaintiff deadline in the securities

ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages UnitedHealth Group Incorporated Investors to Secure Counsel Before Important Deadline in Securities Class Action Commenced by the Firm- UNH

ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages UnitedHealth Group Incorporated Investors to Secure Counsel Before Important Deadline in Securities Class Action Commenced by the Firm- UNH GlobeNewswire May 23, 2025 NEW YORK, May 22, 2025 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of UnitedHealth Group Incorporated (NYSE:

Shareholder Alert: Robbins LLP Informs Stockholders of the Ibotta, Inc. Class Action Lawsuit

Robbins LLPinforms stockholders that a class action was filed on behalf of all persons or entities that purchased or otherwise acquired Ibotta, Inc. (NYSE: IBTA) securities pursuant and/or traceable to the registration statement and related prospectus issued in connection with Ibotta's April 18, 2024 initial public offering, or between April 18, 2024 and February 26,

VTRS Investors Have Opportunity to Lead Viatris Inc. Securities Fraud Lawsuit

https://mma.prnewswire.com/media/2598307/32a64817_10ba_407b_947c_76bd790799f6_Logo.jpg Why:Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Viatris Inc. (NASDAQ: VTRS) between August 8, 2024 and February 26, 2025, both dates inclusive (the “Class Period”), of the importantJune 3, 2025 lead plaintiff deadline. So what: If you purchased Viatris securitiesduring the Class Period you may be entitled

HUTCHMED Highlights Clinical Data to be Presented at the 2025 ASCO Annual Meeting

(NASDAQ:HCM),(LSE – AIM:HCM),(HKSE:0013), HONG KONG and SHANGHAI and FLORHAM PARK, N.J., May 23, 2025 (GLOBE NEWSWIRE) — HUTCHMED (China) Limited (“HUTCHMED“) (Nasdaq/AIM:​HCM; HKEX:​13) today announces that new data from several studies of compounds discovered by HUTCHMED including savolitinib, ranosidenib, fruquintinib and surufatinib, will be presented at the American Society of Clinical Oncology (“ASCO”) Annual Meeting

Great Novel Therapeutics Biotech & Medicals Corporation (GNTbm) Presented Preclinical Data on GNTnm-38, an Novel Epigenetic Immune Activator, at the 2025 ASCO Annual Meeting

GNTbm (stock code: 7427, Taiwan) announced the preclinical data on GNTbm-38, an novel epigenetic immune activator for cancer immunotherapy. GNTbm-38 was presented as posters at the 2025 American Association of Clinical Oncology (ASCO) Annual Meeting, which is held in Chicago, USA, from May 30 to Jun 04, 2025. Abstract: 2574 Title: Preclinical development of GNTbm-38,

CARsgen’s Satri-cel Abstract Available on ASCO Website

CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announces that an abstract of the research results of the confirmatory Phase II clinical trial of satricabtagene autoleucel (“satri-cel”, CT041) (an autologous CAR T-cell product candidate against protein Claudin18.2) for advanced gastric/gastroesophageal junction cancer (G/GEJC) in China (CT041-ST-01, NCT04581473)

Eisai to Present E7386, Co-created by PRISM BioLab and Eisai, at the ASCO (American Society of Clinical Oncology) Annual Meeting

Abstract Released for E7386, Co-Developed Through Collaborative Research Between Eisai and PRISM PRISM BioLab, Co. Ltd. (“PRISM”), a leading discovery and development biotechnology company designing small molecule inhibitors of protein-protein interaction (PPI) targets, today announced that the analysis of a combination study of E7386(*1), created through collaboration research with Eisai Co., Ltd. (“Eisai”), and Lenvatinib

Scroll to Top